**INFORMATION DISCLOSURE STATEMENT**

Applicant : Latta, Paul P.
App. No : 10/823,263
Filed : April 13, 2004
For : A METHOD OF TREATMENT OF
DIABETES THROUGH INDUCTION
OF IMMUNOLOGICAL TOLERANCE
Examiner : Belyavski, Michail A.
Art Unit : 1644

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 7 references to be considered by the Examiner. These references are of record in related application serial no. 10/660,924 filed September 12, 2003, and therefore copies of these references are not enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. 1.97(E)(2)

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to my

Appl. No. : 10/823,263
Filed : April 13, 2004

Docket No. LATTA.002C4
Customer No. 20,995

knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R.1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Thus, no fee is required as set forth in 37 C.F.R. 1.97(c).


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6 May 2005

By: Daniel Altman
Daniel E. Altman
Registration No. 343,115
Attorney of Record
Customer No. 20,995
(949) 760-0404

1700680:kc
050605



PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/823,263
Filing Date	4-13-04
First Named Inventor	Latta, Paul P.
Art Unit	1644
Examiner	Belyavskiy, Michail A.
Attorney Docket No.	LATTA.002C4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	BINGLEY, P.J. et al. (1994) "Combined analysis of autoantibodies improves production of IDDM in islet cell antibody-positive relatives" Diabetes 43:1304(7).	
	2	BONIFACIO, E. et al. (1995) "Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity" Diabetologia 38:816-822.	
	3	CHRISTIE, M.R. et al. (1994) "Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity" Diabetes 43:1254(6).	
	4	LEE, H.C. et al. (1995) "Relationships among 64k autoantibodies, pancreatic beta-cell function, HLA-DR antigens and HLA-DQ genes in patients with insulin-dependent diabetes mellitus in Korea" Korean J. Intern Med. (Abstract only).	
	5	TUOMILEHTO, J. et al. (1994) "Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease" Lancet 343:1383-1385.	
	6	ZIMMET, P.Z. et al. (1994) "Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency" Diabetic Medicine 11:299-303.	
	7	ZIMMET, P.Z. et al. (1994) "Autoantibodies to glutamic acid decarboxylase and insulin in islet cell antibody positive presymptomatic type 1 diabetes mellitus: frequency and segregation by age and gender" Diabetic Medicine 11:866-871.	

1688567:vr
042905

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
T ¹ - Place a check mark in this area when an English language Translation is attached.	